Journal
AMERICAN JOURNAL OF CARDIOLOGY
Volume 111, Issue 1, Pages 38-44Publisher
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2012.08.043
Keywords
-
Categories
Funding
- Abbott Vascular
- AstraZeneca
- CLS Behring
- Daiichi Sankyo
- Eli Lilly
- Biotronik
- Iroko Cardio
- Boston Scientific Corporation
- Cordis Corporation
- Edwards Lifesciences
- Sanofi-Aventis
- Menarini
- European Society of Cardiology
- Bristol-Myers Squibb
- Guerbet Medical
- Medtronic
- Stago
- Fondation de France
- INSERM
- Federation Francaise de Cardiologie
- Societe Francaise de Cardiologie
- Asante
- Atrium
- Bayer
- Boehringer-Ingelheim
- Choice Pharma
- Brahms
- CCS
- CHUV
- Duke Institute
- EuroRSCG
- GLG
- GlaxoSmithKline
- HUG
- Indegene
- Institut de France
- Lead-up
- McKinsey
- MSD
- Nanospheres
- Navigant
- Novartis
- Pfizer
- Portola
- Roche
- Royal College of Physicians
- Stentys
- SGAM
- Springer
- Thrombosis Research Institute
- The Medicines Company
- The Thrombolysis In Myocardial Infarction Group
- US Zurich
- WebMD
- Wolters
- Servier
Ask authors/readers for more resources
The aim of this study was to evaluate platelet reactivity and 30-day bleeding events in patients treated with prasugrel 10 mg after acute coronary syndromes. A total of 444 patients with acute coronary syndromes treated with percutaneous coronary intervention and prasugrel 10 mg/day were monitored by measurement of the vasodilator-stimulated phosphoprotein (VASP) index 2 to 4 weeks after hospital discharge. Platelet reactivity was also assessed using the VerifyNow P2Y(12) assay and light transmission aggregometry. Bleeding events (per the Bleeding Academic Research Consortium [BARC] definition) and ischemic events (death, myocardial infarction, and definite stent thrombosis) were collected over 30 days of follow-up. Two thirds of the patients. presented with ST-segment elevation myocardial infarctions, 28.8% had diabetes, and 12.4% were aged > 75 years. High on-treatment platelet reactivity according to 3 prespecified definitions (VASP index >= 50%, platelet reactivity >= 235 P2Y(12) reaction units, and residual platelet reactivity >= 46.2%) was found in 6.8%, 3.4%, and 3.2% of patients, respectively. Obesity (body mass index > 30 kg/m(2)) and multivessel disease were the only independent factors associated with high on-treatment platelet reactivity (p = 0.006 and p = 0.045, respectively). At 30 days, there was no major bleeding complication (BARC grade 3 or 5), and 1.6% of patients had recurrent ischemic events. Nuisance bleeding (BARC grade 1) and minor bleeding (BARC grade 2) occurred in 14.2% (n = 63) and 2.5% (n = 11) of patients, respectively, but were not predicted by VASP index. In conclusion, patients with acute coronary syndromes receiving maintenance doses of prasugrel have low rates of HPR and ischemic events within the first month. Minor or minimal bleeding is frequent, but not major bleeding. VASP was poorly correlated with the risk for minor or minimal bleeding. (c) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:38-44)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available